OneVentures Welcome Image

OneVentures is a venture capital firm headquartered in Sydney, Australia that provides human and investment capital into high growth companies with a particular focus on transformative technologies.

The firm is particularly focused on opportunities originating in Australia which are poised to expand into the established and emerging global markets.

All of our Partners have founded, built and exited high-growth businesses.

Our goal is to be the leading Australian venture capital company.

Proudly supporting

Heads Over Heels
Investor Portal Log In

Connect With Us

About OneVentures

OneVentures invests in technology companies that serve or disrupt large high growth global markets. The firm has $170M in funds under management recently launching its new Innovation and Growth Fund II which is focused on growth and expansion stage technology companies.

OneVentures is managed by a team of Partners with a skill-set and track record ideally suited to collaboration with entrepreneurial management teams to foster growth and create value: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, extensive off-shore experience and networks.

The OneVentures team is committed to deliver investor returns by applying this expertise to select portfolio companies with significant potential then accelerating their performance.


OneVentures Management Pty Ltd is a designate under OneVentures Nominees Pty Ltd's AFSL (Licence No: 462825) issued by the Australian Securities and Investments Commissions, authorising the Manager to provide such financial services as the Manager provides during the course of its duties as manager of the Fund.

The OneVentures Team

All Partners have many years of C-level, board and investment experience. Coupled with this is a track record of identifying investment opportunities in global markets with strong international business backgrounds and networks. The OneVentures Investment team has 7 technology related higher degrees.

Dr Michelle Deaker

Dr Michelle Deaker
Managing Director and CEO

Dr Paul Kelly

Dr Paul Kelly
Partner and Managing Director

Anne-Marie Birkill

Anne-Marie Birkill
General Partner and Executive Director

Graeme Wald

Dr Graeme Wald
Venture Partner

Daniel Gammell

Daniel Gammell
Investment Manager

Dr Amir Zalcenstein

Dr Amir Zalcenstein
Investment Manager, Healthcare

Helen Liu

Helen Liu
Chief Financial Officer

Jelly Jakob

Jelly Jakob


Innovation Fund (Fund I)

The OneVentures Innovation Fund is a $40M venture capital fund formed as an early stage venture capital Limited Partnership. This Fund was launched in 2010 with the Commonwealth Government committing $20M from its IIF programme and this funding matched by high net-worth wholesale investors.

Innovation and Growth Fund (Fund II)

The OneVentures Innovation and Growth Fund was launched in March 2014 with a target of $100M and reached that target in December 2015. Fund II is an early stage venture capital limited partnership backed entirely by Australian high net-worth wholesale investors.

Focusing on later stage (Series B and beyond) investments while still maintaining some investment activity in the earlier stage investments, Fund II is now screening investment opportunities where the experience of the OneVentures management team can be leveraged to accelerate value creation and company success.

We are currently looking for truly transformative companies to join our portfolio of innovative companies, if you think your company has what it takes, read our Application for Funding page and submit your application now.

Information for stakeholders interested in the Significant Investment Visa (SIV) Programme

Information for stakeholders interested in the Significant Investment Visa Programme can be found here.

Investment Portfolio

OneVentures Innovation Fund (Fund I)

OneVentures Innovation and Growth Fund (Fund II)

Other Investments

Latest News

  • Media Release - Icon Group signs up Charm Health to support cancer care

    by Honner | Apr 19, 2016
    Contracts to implement CHARM oncology information system across Icon Cancer Care centres

    Specialist medical technology company Charm Health has signed a contract to install its CHARMTM oncology information management system throughout the day hospital network of Icon Cancer Care.

    Icon Cancer Care is a division of the Icon Group, Australia’s fastest growing integrated cancer care provider. The initial five-year contract will assist in the management of more than 77,000 patient treatments each year across Icon’s six care centres - five in Queensland and one in South Australia. 

    Charm Health is Australia’s leading developer and supplier of specialist oncology eHealth systems. CHARM, its flagship product, is a comprehensive solution designed to manage the clinical and administrative coordination of all aspects of cancer care.

    CHARM supports a multi-disciplinary team approach that improves communication between the care providers which is key to delivering safe and effective care.

    Charm Health Chief Executive Officer Gary Lakin said the partnership with Icon highlighted the increasing demand for more precise management of cancer care. 

    “Icon is the fastest growing private provider of cancer care in Australia.  We are looking forward to working with a company of such high calibre and strong vision,” Mr Lakin said. 

    We developed CHARM as a tool to support good clinical governance and mitigate the risks inherent with the complexity of cancer care. . The agreement is a great endorsement of our solution, in addition to our deep understanding of medical oncology management. 

    “Our partnership with Icon builds on CHARM’s footprint across 50 locations in Australia,” he said. 

    Icon Group Chief Executive Officer Mark Middleton said Charm Health will support the rapid growth Icon expects over the next few years.

    “After an extensive search and evaluation process across Australia and the US over the past 18 months, Charm Health was selected as the preferred provider. 

    “We are committed to delivering high quality comprehensive cancer care services. The selection of CHARM underscores Icon’s commitment to the delivery of quality patient care through best practice, evidence-based medicine,” Mr Middleton said. 

    “CHARM systems, reporting and analytics will help provide additional tools to support Icon’s already strong culture around sound clinical governance.”

    Charm Health Chief Clinical Advisor Teresa Lynne said: “Clinical governance is front of mind for the health care industry. Providers need stronger systems that support best practice governance to ensure they continue to provide the highest quality of care. 

    “I have been involved with the company for over 10 years and have seen the benefits more robust digital management systems can have on patient outcomes.”


    For more information contact:

    Jessica Effeney, Honner 
    Tel: +61 2 8248 3745

    Gary Lakin, Charm Health
    Tel: +61 7 3512 5305

    About Charm Health
    Charm Health is Australia’s leading supplier of specialist oncology eHealth systems with over 50 successful deployments to Australian public and private cancer care providers since 2000.  In the past decade over 65,000 patients have had their treatment managed using Charm Health solutions.  Charm Health’s flagship product CHARM™ delivers comprehensive multi-site functionality that manages the clinical and administrative coordination of all aspects of a patient’s cancer care. Charm Health solutions mitigate compliance, clinical, financial and administrative risk by ensuring the most up to date patient information is available to all healthcare providers, in real time, when making important clinical and prescribing decisions.
    Charm Health is a portfolio company of the OneVentures Innovation Fund.
    Read more about Charm Health at: 
    About Icon Cancer Care

    Icon Cancer Care is the largest provider of private cancer care in Australia, and the only private hospital specialising in oncology. Icon has over 27 years of experience in caring for and treating cancer patients. This is delivered across 6 day hospitals in Queensland and South Australia, including a centre in Townsville, which is the only regional hospital in Australia dedicated to cancer care. Icon manages more than 77,000 treatments each year through a network of more than 100 doctors and over 380 staff.

    Icon has a proud history of pioneering private cancer care in Australia and operating best practice cancer clinical trials through their not-for-profit partner, Icon Cancer Foundation. Icon Cancer Care is currently accredited by the ACHS.
    Read more about Icon Cancer Care at:

Full story

Contact Us

For Entrepreneurs

We are now screening companies for OneVentures Fund II which is a Series A and beyond growth fund focusing on the technology sector. To qualify for funding, your company should meet the following criteria:

  • Australian domiciled company
  • We invest in technology companies from many sectors, but we are particularly interested in companies from the following sectors: healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics or food security
  • If a life sciences company, your product should have a strong proof of concept and be at a minimum, in a late stage clinical trial and/or well progressed through the regulatory process
  • If from another sector, your company should be generating sustainable revenue and have a strong market validation
  • Approaching profitability with capital required to fuel growth and global expansion

If you meet the above criteria, send us a brief document (a 2-page executive summary or introductory PowerPoint is sufficient, please do not send larger documents or full information memorandums at this stage) covering at a minimum the following points to

  • Summarize in 2 sentences what your company does (this is important)
  • Identify the market, value proposition and your competitive advantage
  • Tell us about your progress to date
  • State your revenue for the last financial year and projected revenue for current financial year
  • Indicate capital required and how it will be used
  • Include 3 point bios of each executive and contact details

We will review your proposal and endeavour to revert to you within 2 weeks. 


For Investors

Investor enquiries:

Information for stakeholders interested in the Significant Investment Visa (SIV) Programme

The Significant Investor Visa (SIV) programme was revised with the announcement in May 2015 of a new complying investment framework. The new framework mandated that SIV applicants would be required to invest a minimum of $500,000 at the at time of investment in an AusIndustry registered fund(s): that is, a VCLP, ESVCLP or an Australian VC fund-of-fund as registered under the Venture Capital Act 2002. The minimum amount is expected to be increased within two years as the market responds.

The Austrade website has more information regarding the programme available, including information sheets in English and Chinese.

The relevant regulations can be accessed here.

OneVentures is not at this time accepting new capital commitments and is therefore not in a position to receive funding from individual SIV applicants. When this situation changes we will provide details here and on the AVCAL website.

We are however receiving proposals from SIV Fund of Funds interested in becoming a OneVentures SIV partner for 2016 and beyond. If you represent a Fund of Funds and meet the following criteria we request you submit a brief proposal for our consideration.

Our criteria:

  • You should have a track record in servicing SIV applicants
  • You should have an established Australian AML/CTF KYC compliance framework that OneVentures can rely on in accepting SIV funding
  • You should be an AusIndustry compliant fund of funds structure – OneVentures will not accept direct investment from individual SIV applicants at this stage
  • You should have a fund of funds structure that can invest the capital for up to 10 years in line with our funding cycle

Your proposal should address those key criteria and provide information about:

  • The Directors
  • The Management Team
  • Your track record in providing SIV applicants with a return on investment
  • How you will ensure AML/CTF KYC compliance including details of any external providers that support this process
  • Details of any relevant reporting and financial operational requirements we should consider
  • Your ability to source capital and the % of SIV market you currently hold/expected quantum of capital you would be looking to deploy p.a. to VC

We plan to work with up to 3 such partners only and will determine the parties with whom we wish to progress discussions by December 2015.


General Enquiries

General enquiries:
Telephone: +61 2 8205 7379


OneVentures Pty Ltd
Suite 304, Level 3
1 Alfred Street
Sydney NSW 2000


c/- Interfinancial
Level 3, 145 Eagle Street
Brisbane QLD 4000


For Media Enquiries

For an interview with a OneVentures' spokesperson, please contact Honner Media at +61 2 8248 3744.